Amylyx ($AMLX): Can Avexitide Reach an NDA Filing by Year-End?

01 Bull, middle and bear scenarios

What changed in the scenario tree

The bear case is no longer primarily “the pivotal trial fails.”

It has moved downstream toward regulatory interpretation, commercial execution and valuation.

That is a meaningful improvement in fundamental quality even though it does not eliminate equity risk.

What Would Falsify This Reading

This page reads Amylyx as a company that has changed category: a pivotal trial that worked, a filing to prepare, and enough money to reach a launch. Five things would show that reading to be wrong, and each is checkable against a filing, a regulator record or a company release.

• The application is not filed by the end of 2026. The company targets submission by year end and has published no day. A slip, or a filing that the FDA refuses to accept for review, would move the whole timetable and would be the first evidence that turning a positive trial into a dossier is harder than it looked in August.
• The full LUCIDITY dataset says something the topline did not. What was announced on August 18, 2026 is a 55% reduction in the composite rate of Level 2 and Level 3 events against placebo, at p=0.000003, in 78 participants. Presentation or publication would add the confidence intervals, the analysis population, the missing-data handling and the full adverse-event table. A trial this small can meet an endpoint convincingly and still leave open questions about who benefits.
• The addressable population turns out to be smaller than the model. Post-bariatric hypoglycaemia is described here as affecting roughly 160,000 people in the United States. That figure is an estimate of prevalence, not of diagnosed and treated patients. A launch reveals how many are actually identified, referred and reimbursed, and that number is usually a fraction of the first.
• The money is spent faster than planned. $250.8 million of cash and investments at June 30, 2026, before an offering that closed on August 21 with the full option exercised for about $575 million gross, against a quarterly net loss of $43.4 million. A commercial build for a first launch is the phase in which that rate changes.
• The rest of the pipeline produces something. AMX0035 in Wolfram syndrome, AMX0114 and AMX0318 all sit behind avexitide with no dated readouts. A positive result in any of them would make this more than a one-asset company; the history of AMX0035 in amyotrophic lateral sclerosis is the reason that is worth watching rather than assuming.

None of these is a prediction. They are the observations that would make the rest of this page wrong, listed so that a reader can check them rather than take the reading on trust.

September 24, 2026 update

On September 23, 2026 Amylyx announced a fireside chat at the Stifel 2026 Virtual Cardiometabolic Forum on September 30 at 9:30 a.m. ET, webcast live with a 90-day replay (release). It is an investor appearance; it sets no date for the avexitide NDA, which remains targeted by year-end 2026.

September 23, 2026

The September 8 filing adds a Bachem manufacturing agreement and a Polypeptide term sheet. These support launch preparations if approved; they do not establish approval or commercial demand.

Company release and event pages were checked through September 23; no later material clinical release was identified. Preserve the difference between the June cash balance, estimated offering proceeds and a current cash balance. The manufacturing term sheet and final contract are different legal stages. Older references to upcoming September conferences are historical.

Manufacturing commitments disclosed

September 8, 2026 — Bachem agreement dated September 8; Polypeptide term sheet dated September 1 with a $30 million capacity-reservation fee. A definitive Polypeptide agreement remained to be negotiated under the filing. Source

Morgan Stanley appearance now past

September 8, 2026 — The September 15 fireside chat is listed among past events. The checked event page shows no scheduled upcoming event; NDA guidance is a separate company target. Source

Upsized equity offering priced

August 19, 2026 — 14.09 million shares at $35.50 imply approximately $500.2 million gross before fees, excluding the additional-share option. The pricing announcement expected closing August 21 subject to conditions. Source

LUCIDITY reaches primary endpoint

August 18, 2026 — In 78 participants, the composite Level 2/3 hypoglycemia event rate fell 55% versus placebo through week 16 (p=0.000003). The result supports a planned NDA, not approval. Source

The August 21, 2026 offering closed with the option fully exercised: 16,203,500 new shares and about $575 million gross. The prospectus estimates about $542.5 million net for that completed size. Adding that estimate to June 30 cash and securities $250.760 million gives $793.260 million, a calculation before subsequent spending and commitments, not a reported current balance. The June 30 share count 111,368,283 plus the new offering shares equals 127,571,783 before other intervening issuances or exercises. August prospectus · Closing confirmation.

Previous dated context and snapshots

The historical blocks below preserve their original observation dates. The current update above supersedes references to the latest news or next event in these earlier snapshots.

Amylyx has crossed the biggest clinical hurdle in its current story. Phase 3 LUCIDITY showed a 55% reduction versus placebo in the FDA-agreed composite rate of Level 2 and Level 3 hypoglycemic events, with p=0.000003 and all reported secondary endpoints met. The debate now moves from pivotal efficacy risk toward FDA execution, label scope, commercialization, pricing, reimbursement and whether avexitide can establish the first approved treatment franchise in post-bariatric hypoglycemia.

Amylyx announced a management fireside chat at the 24th Annual Morgan Stanley Global Healthcare Conference on September 15, 2026 at 12:20 p.m. ET. The webcast is accessible from the company’s Events and Presentations page, with replay available for 90 days. This is an investor presentation, not a promised clinical readout; the announcement does not change the trial milestones below.

02 Latest verified development: LUCIDITY clears the pivotal efficacy hurdle

On August 18, 2026, Amylyx reported positive topline results from the pivotal Phase 3 LUCIDITY study of avexitide in adults with post-bariatric hypoglycemia following Roux-en-Y gastric bypass.

The study met its FDA-agreed primary efficacy endpoint. Participants receiving avexitide experienced a 55% reduction versus placebo in the composite rate of Level 2 and Level 3 hypoglycemic events through Week 16, with a reported p-value of 0.000003.

Amylyx also reported that all disclosed secondary efficacy endpoints were met, including measures of Level 2 hypoglycemia recorded through self-monitored blood glucose, Level 2 events captured by continuous glucose monitoring and independently adjudicated Level 3 events.

The reported safety profile remained favorable. Most adverse events were mild or moderate, no treatment-related serious adverse events were reported, and common adverse events included diarrhea and injection-site reactions such as erythema and bruising. Amylyx also reported no meaningful change in body weight during the 16-week controlled period.

Amylyx now plans to submit a New Drug Application for avexitide by the end of 2026.

03 The short answer

Amylyx is no longer primarily a pre-readout Phase 3 biotech story.

Before August 18, most near-term AMLX value rested on one question: would LUCIDITY work?

The initial answer is clearly positive. The trial produced a large treatment effect, extremely strong statistical significance, consistency across reported secondary endpoints and no obvious new safety problem in the topline disclosure.

That changes the investment debate.

The next questions are now:

• Will FDA accept the NDA package without additional controlled efficacy work?
• How broad will the requested and eventual label be?
• Will manufacturing and CMC be ready for a timely review?
• How much of the headline PBH population is realistically diagnosable and treatable?
• What pricing and reimbursement structure will Amylyx obtain?
• How willing will patients be to remain on a daily subcutaneous therapy?
• Can the company execute a 2027 launch without recreating excessive financing pressure?

Merlintrader research posture: high-interest late-stage biotech transitioning toward regulatory and commercial execution. The clinical setup is materially stronger after LUCIDITY, but approval and commercial success remain unproven.

04 What changed on August 18

05 Why $AMLX matters now

AMLX is unusual because the company is simultaneously a recovery story, a pivotal-data story and a potential new-market-creation story.

Amylyx was previously defined by RELYVRIO, a drug that obtained U.S. approval for ALS and was later voluntarily removed from the market after the confirmatory Phase 3 PHOENIX trial failed.

The company then used its remaining balance sheet to acquire avexitide from Eiger BioPharmaceuticals during Eiger’s bankruptcy process for approximately $35.1 million.

That acquired asset has now delivered the strongest late-stage controlled clinical validation in Amylyx’s post-RELYVRIO history.

That sequence is why AMLX deserves more than a one-line “Phase 3 positive” headline.

06 Company profile and strategic reset

Amylyx Pharmaceuticals is a Cambridge, Massachusetts-based pharmaceutical company listed on the Nasdaq Global Select Market under $AMLX.

The pipeline now spans endocrine and neurodegenerative disease, with four principal investigational programs:

• Avexitide in post-bariatric hypoglycemia and additional hyperinsulinemic conditions.
• AMX0035 in Wolfram syndrome.
• AMX0114 in amyotrophic lateral sclerosis.
• AMX0318, a next-generation long-acting GLP-1 receptor antagonist.

Despite this broader portfolio, the current equity is still primarily an avexitide story.

AMX0035 remains clinically interesting in Wolfram syndrome but does not have randomized pivotal efficacy evidence. AMX0114 is in Phase 1. AMX0318 is still preclinical.

07 Avexitide science: blocking GLP-1 rather than activating it

Avexitide is an investigational peptide and a GLP-1 receptor antagonist.

That mechanism is notable because GLP-1 receptor agonists dominate current diabetes and obesity headlines. Avexitide approaches a very different biological problem from the opposite direction.

In post-bariatric hypoglycemia, an exaggerated GLP-1 response after food can contribute to excessive insulin secretion. Blood glucose then falls rapidly, producing recurrent hypoglycemia.

Avexitide is designed to bind to the GLP-1 receptor on pancreatic beta cells and inhibit GLP-1 activity, thereby reducing inappropriate insulin secretion and stabilizing glucose.

This gives the program a relatively intuitive mechanistic chain:

Mechanistic plausibility is useful, but the investment case no longer rests only on biology. Amylyx now has randomized Phase 3 clinical evidence.

08 Post-bariatric hypoglycemia: real unmet need, uncertain commercial denominator

Post-bariatric hypoglycemia can develop after bariatric surgery and cause recurrent episodes of clinically significant low blood glucose.

Severe events may produce impaired cognition, loss of consciousness or seizures. The condition can interfere with work, driving, independent living and normal daily activity.

Amylyx estimates that PBH affects approximately 8% of people in the United States who have undergone the two most common bariatric procedures, corresponding to roughly 160,000 people.

There is currently no FDA-approved therapy specifically for PBH.

The 160,000 number is not the same as an immediate sales population

Investors should not simply multiply 160,000 by a theoretical annual drug price.

LUCIDITY specifically enrolled patients with PBH after Roux-en-Y gastric bypass. The broader prevalence estimate also includes other bariatric populations.

Commercial conversion will depend on:

• the exact FDA-approved label;
• severity thresholds;
• diagnosis rates;
• specialist referral;
• payer criteria;
• response to dietary or off-label management;
• daily injection acceptance;
• pricing;
• persistence on chronic treatment.

09 LUCIDITY Phase 3: trial design and topline result

Why p=0.000003 matters — and what it does not mean

The p-value indicates that the observed treatment separation is extremely unlikely to be explained by random variation under the null hypothesis.

It does not prove that every treated patient improved by 55%, nor does it guarantee FDA approval or commercial success.

The 55% number refers to the relative difference in the event rate between treatment groups for the composite primary endpoint.

10 Prior evidence: LUCIDITY replicated rather than invented the signal

The Phase 3 result is more persuasive because the direction is consistent with earlier controlled avexitide studies.

In the prior Phase 2b study, the 90 mg once-daily dose later selected for LUCIDITY produced:

• a statistically significant 53% reduction in Level 2 hypoglycemic events with p=0.004;
• a statistically significant 66% reduction in Level 3 hypoglycemic events with p=0.0003.

Earlier PREVENT data also showed significant reductions in clinically important hypoglycemia.

That is a substantially cleaner development history than a program whose pivotal success appears unexpectedly after inconsistent earlier evidence.

11 Regulatory path: NDA becomes the next valuation checkpoint

Avexitide has several FDA designations that matter operationally but should not be confused with approval.

• Breakthrough Therapy Designation in post-bariatric hypoglycemia.
• Breakthrough Therapy Designation in congenital hyperinsulinism.
• Rare Pediatric Disease Designation in congenital hyperinsulinism.
• Orphan Drug Designation for hyperinsulinemic hypoglycemia.

Amylyx now intends to submit the avexitide NDA by the end of 2026.

What still has to happen

1. NDA preparation and completion.
2. Formal submission.
3. FDA filing acceptance.
4. Review classification and potential review timeline.
5. Clinical and statistical review.
6. CMC and manufacturing review.
7. Label negotiation.
8. Potential inspection and other pre-approval requirements.
9. Final FDA decision.

The label may matter almost as much as approval

LUCIDITY studied PBH after Roux-en-Y gastric bypass. Investors should watch closely for the population Amylyx requests in the NDA and the population FDA ultimately grants.

A narrower initial label could reduce the immediately addressable market even if the drug is approved.

12 Pipeline map

13 AMX0035 in Wolfram syndrome: intriguing signal, high proof burden

AMX0035 remains in development for Wolfram syndrome despite its failed controlled programs in ALS and progressive supranuclear palsy.

The HELIOS Phase 2 study enrolled only 12 adults in a single-site, single-arm, open-label design.

Amylyx has reported encouraging observations across pancreatic beta-cell function, glycemic measures, vision-related outcomes and patient or clinician assessments.

Longer-term follow-up has provided additional durability observations, but the evidentiary limitations remain fundamental.

The market should wait for a clearly defined Phase 3 protocol, endpoints, FDA alignment and controlled efficacy evidence before assigning Wolfram syndrome a valuation weight comparable with avexitide.

14 AMX0114 and AMX0318: longer-duration pipeline optionality

AMX0114 — ALS

AMX0114 is an antisense oligonucleotide designed to reduce calpain-2, a protein implicated in axonal degeneration.

It is being evaluated in the Phase 1 LUMINA dose-ranging trial in ALS. Initial company updates have focused primarily on safety, tolerability, pharmacology and biomarker behavior.

This is an early human program. A favorable Phase 1 safety profile would justify continued development but would not establish clinical efficacy in ALS.

AMX0318 — long-acting GLP-1 receptor antagonist

AMX0318 emerged from Amylyx’s collaboration with Gubra and was selected as a next-generation long-acting GLP-1 receptor antagonist development candidate.

The strategic logic becomes more interesting after LUCIDITY.

If avexitide validates GLP-1 antagonism commercially, a longer-acting successor could potentially:

• reduce dosing burden;
• improve convenience;
• extend the PBH franchise;
• support lifecycle management;
• expand into additional endocrine indications.

Amylyx has targeted an IND in 2027.

15 RELYVRIO and ORION: the history investors should not erase

Amylyx’s current success should not be analyzed without its earlier failures.

RELYVRIO / AMX0035 in ALS

RELYVRIO received FDA approval for ALS in 2022.

The subsequent global Phase 3 PHOENIX trial failed to demonstrate a statistically significant benefit on its primary ALSFRS-R endpoint at Week 48. Amylyx reported p=0.667, with no statistically significant benefit on the main secondary outcomes.

Amylyx then initiated the voluntary removal of RELYVRIO and ALBRIOZA from the U.S. and Canadian markets.

The company also implemented a major restructuring and workforce reduction.

ORION in progressive supranuclear palsy

In 2025 Amylyx discontinued the ORION PSP program after the controlled Phase 2b study showed no meaningful difference from placebo on the primary or secondary outcomes at Week 24.

Management deserves credit for acquiring and advancing avexitide. That credit does not require pretending the previous clinical record never happened.

16 Financial position and runway

The August 21, 2026 offering closed with the option fully exercised: 16,203,500 new shares and about $575 million gross. The prospectus estimates about $542.5 million net for that completed size. Adding that estimate to June 30 cash and securities $250.760 million gives $793.260 million, a calculation before subsequent spending and commitments, not a reported current balance. The June 30 share count 111,368,283 plus the new offering shares equals 127,571,783 before other intervening issuances or exercises. August prospectus · Closing confirmation.

September 8, 2026: The September 8 Form 8-K discloses a definitive Bachem manufacturing agreement signed that day and a September 1 Polypeptide term sheet. Amylyx will pay Polypeptide a $30 million upfront fee for capacity reservation. Minimum annual purchasing commitments start in 2028; Polypeptide supply terms remain subject to execution of a definitive agreement. Both suppliers are non-exclusive. This prepares commercial supply if avexitide is approved; it is neither approval nor evidence of product revenue, and the fee is a cash commitment rather than financing proceeds. Primary source

Amylyx entered the LUCIDITY readout with a substantially stronger balance sheet than many late-stage small and mid-cap biotech companies.

The August 21, 2026 offering closed with the option fully exercised: 16,203,500 new shares and about $575 million gross. The prospectus estimates about $542.5 million net for that completed size. Adding that estimate to June 30 cash and securities $250.760 million gives $793.260 million, a calculation before subsequent spending and commitments, not a reported current balance. The June 30 share count 111,368,283 plus the new offering shares equals 127,571,783 before other intervening issuances or exercises. August prospectus · Closing confirmation.

That sequential balance change should not automatically be treated as a normalized quarterly burn rate because changes in working capital, investment maturities and other cash-flow items can make the headline cash movement differ from operating cash consumption.

17 Capital structure and dilution: current runway came at a real cost

The August 21, 2026 offering closed with the option fully exercised: 16,203,500 new shares and about $575 million gross. The prospectus estimates about $542.5 million net for that completed size. Adding that estimate to June 30 cash and securities $250.760 million gives $793.260 million, a calculation before subsequent spending and commitments, not a reported current balance. The June 30 share count 111,368,283 plus the new offering shares equals 127,571,783 before other intervening issuances or exercises. August prospectus · Closing confirmation.

Amylyx’s strong current balance sheet was built through substantial equity financing.

During 2025 the company completed major public offerings that materially increased its share count. The September 2025 transaction alone generated approximately $190.7 million of net proceeds.

Earlier 2025 financing also contributed more than $65 million of net capital.

The August 21, 2026 offering closed with the option fully exercised: 16,203,500 new shares and about $575 million gross. The prospectus estimates about $542.5 million net for that completed size. Adding that estimate to June 30 cash and securities $250.760 million gives $793.260 million, a calculation before subsequent spending and commitments, not a reported current balance. The June 30 share count 111,368,283 plus the new offering shares equals 127,571,783 before other intervening issuances or exercises. August prospectus · Closing confirmation.

Additional financing still remains possible if Amylyx accelerates its commercial infrastructure, broadens avexitide development, acquires another program or chooses to increase post-launch flexibility.

The distinction that mattered in the previous version of this page has now been settled by events: the company did issue more equity, three days after the readout, and the useful question is no longer whether it would but what the money is for. The prospectus says the launch of avexitide in the United States, if approved, manufacturing included.

18 Institutional ownership, founders and governance

The August 21, 2026 offering closed with the option fully exercised: 16,203,500 new shares and about $575 million gross. The prospectus estimates about $542.5 million net for that completed size. Adding that estimate to June 30 cash and securities $250.760 million gives $793.260 million, a calculation before subsequent spending and commitments, not a reported current balance. The June 30 share count 111,368,283 plus the new offering shares equals 127,571,783 before other intervening issuances or exercises. August prospectus · Closing confirmation.

Amylyx’s 2026 proxy showed a meaningful institutional and specialist-biotech ownership base.

These percentages are historical filing snapshots and should not be treated as a live ownership register.

Founder-led structure

Amylyx continues to be led by co-founders Joshua Cohen and Justin Klee, who serve as Co-Chief Executive Officers.

Founder ownership provides alignment, while the company’s prior clinical and commercial history means execution should still be judged on evidence rather than personality.

19 Avexitide intellectual property: do not reduce it to one expiry date

The avexitide IP estate contains several separate patent families with different scopes and potential expiry dates.

These dates exclude possible patent-term adjustment, patent-term extension, terminal disclaimers and other legal factors.

20 Competition and commercialization: Amylyx may have to build the PBH market

Avexitide enters an unusual commercial setting because there is currently no FDA-approved therapy specifically for PBH.

That creates an obvious advantage: Amylyx does not need to displace another approved branded PBH drug on day one.

But it also creates a challenge: the company may have to build the treatment market itself.

Commercial execution will require

• greater physician awareness;
• consistent diagnosis pathways;
• specialist and bariatric-center education;
• referral networks;
• payer policies;
• patient identification;
• clear treatment-duration expectations;
• support for chronic injectable use.

Daily injection is not a trivial detail

Severe PBH can justify meaningful treatment burden, but chronic daily subcutaneous administration may still affect uptake and persistence.

That is why AMX0318 could become strategically important if its long-acting profile eventually translates into human development.

21 Valuation framework: the stock now needs a post-Phase-3 model

A conventional “cash plus pipeline” framework is no longer sufficient after LUCIDITY.

Avexitide now deserves a probability-adjusted commercial model, but a responsible model still requires several unknowns.

A serious AMLX model needs assumptions for:

• probability of NDA acceptance;
• probability of FDA approval;
• label breadth;
• eligible PBH population;
• diagnosis rate;
• annual treatment price;
• gross-to-net discounts;
• payer restrictions;
• penetration curve;
• treatment duration and persistence;
• commercial expense;
• royalties inherited with the avexitide transaction;
• future diluted share count;
• discount rate;
• terminal competition and exclusivity.

Small changes to those assumptions can produce very large changes in theoretical equity value.

The cleaner question is whether the market is pricing avexitide as:

1. a successful Phase 3 asset awaiting regulatory review;
2. a probable first-in-class commercial product;
3. or an already mature commercial franchise.

Those are very different valuation states.

Market positioning

Finviz snapshot read October 2, 2026: market capitalization 3.50B USD, provider shares outstanding 111.37M, float 106.27M, short float 12.72% (13.51M shares short), short ratio 5.81; institutional ownership 85.62% and insider ownership 15.34%. The previous regular-session close was $28.08 on October 1. The observation date is not the short-interest settlement date; these provider fields do not replace the dated company share count. Finviz.

22 Catalyst map: what comes next after Phase 3

23 Risk register and thesis falsifiers

The central thesis falsifier has changed.

Before August 18 it was: “LUCIDITY fails to demonstrate a clinically persuasive reduction in hypoglycemic events.”

That risk has now been substantially resolved.

The new falsifier is: “Amylyx fails to convert a strong pivotal result into an approvable, commercially useful and sustainably protected product.”

24 Merlintrader bottom line

Amylyx entered August 18 as a high-stakes pivotal biotech.

It leaves the LUCIDITY topline announcement as something different: a pre-NDA, potentially pre-commercial endocrine company with a successfully replicated pivotal asset.

LUCIDITY delivered the result investors needed to see:

• FDA-agreed primary endpoint met;
• 55% reduction versus placebo;
• p=0.000003;
• all reported secondary endpoints met;
• no treatment-related serious adverse events reported;
• NDA targeted by year-end 2026.

The result substantially de-risks the clinical thesis.

It does not automatically answer the next set of questions.

The historical context makes the setup even more unusual.

Amylyx went from RELYVRIO approval to confirmatory failure and withdrawal, then purchased avexitide from a bankrupt company for roughly $35 million, recapitalized the balance sheet and produced a strongly positive pivotal Phase 3 trial.

That does not erase the mistakes or failures that came before.

It does mean that the current Amylyx thesis deserves to be judged on its current evidence.

And as of August 18, 2026, the evidence behind avexitide is materially stronger than it was one day earlier.

26 Follow the next AMLX catalyst

The next AMLX updates should focus on detailed LUCIDITY data, FDA/NDA language, open-label-extension follow-up and commercial preparation rather than repeatedly restating the topline headline.

Join @merlintraderpub_com · Open the Biotech Catalyst Calendar · Top Ten Biotech Stocks Right Now

Data cut-off: August 18, 2026, approximately 8:10 a.m. ET. The LUCIDITY topline release is included. The investor call began at 8:00 a.m. ET; this version intentionally excludes call commentary that had not yet been independently verified at the cut-off.